Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

In our BTK degrader clinical program ... the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases.

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

TG Therapeutics' strong cash position and Briumvi success fuel growth potential. Find out why TGTX stock is rated a strong ...

Merit Medical Systems, Inc. MMSI, on Monday, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus ...

The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Dr. Owen Witte(Link is external) (Link opens in new window) with the twelfth ...

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improvements in disease ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

By Tom Delavan With its radical buildings by Eliel Saarinen and Alvar Aalto, the Finnish capital is one of Europe’s most fascinating, if lesser-sung, design capitals. By Michael Snyder The ...